Sonoma Pharmaceuticals posts 60% revenue rise, first positive EBITDA

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Sonoma Pharmaceuticals posts 60% revenue rise, first positive EBITDA

Sonoma Pharmaceuticals Delivers 141% U.S. Revenue Growth in FY Q1, 60% Total Revenue Growth and First-Ever Positive Adjusted EBITDA

August 6, 2026 9:01 AM EDT

Total revenue increased 60% year over year to $6.4 million

Net loss per share decreased 88% compared to the prior-year quarter

Gross margin expanded to 40% as operating expenses remained stable

FDA clearance and new global distributors support continued commercial growth

BOULDER, CO / ACCESS Newswire / August 6, 2026 / Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA), a global healthcare leader developing and producing patented Microcyn® technology-based stabilized... More